Adolescent-tailored HIV treatment and prevention strategies in south africa: projecting clinical benefits and value

Active Project Grant Awarded Last action

Award ID
R01HD111355
Recipient
Awarding agency
Obligated
$6,379,319

Award facts

Completion date 83% complete
Place of performance
Boston, MA 02114, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Globally, HIV-related deaths have decreased 60% from their peak in 2004. Adolescents and young adults (AYA) ages 10 to 24, however, comprise the only age group that has not seen improvements in HIV-related mortality since then. Adolescence is a distinct developmental period, in which risk-taking and impulsive decision-making are normative behaviors. Stigma, disclosure concerns, and medication toxicity impact HIV health behaviors at a time when AYA may also experience their first sexual relationships. Differences in HIV health outcomes by age are partly due to late diagnosis, as well as to challenges in accessing treatment and prevention modalities requiring daily adherence. This problem is particularly acute in south africa, which has the largest HIV epidemic in the world, with one in three new infections there occurring among AYA. Recent advances in long-acting HIV prevention and treatment formulations that avert the need to take a daily pill hold major promise, particularly for AYA. With support to DR. Neilan from an nichd K08 HD094638 (2018-2023) as well as from the adolescent medicine for HIV/aids interventions trials network U24HD089880 (2017-2022), we developed the cost-effectiveness of preventing aids complications-adolescent and young adult (cepac- AYA) microsimulation model. We have conducted 12 model-based clinical and cost-effectiveness analyses addressing key questions in AYA HIV prevention, diagnosis, and treatment in the united states. In a new US- south africa collaboration, we now propose to adapt and expand the structure of this simulation model and assemble necessary data inputs, and then to use the model to identify the most effective and cost-effective approaches and monitoring strategies for the treatment and prevention of HIV among AYA in south africa. We have three specific aims: aim 1. Develop new structure within the cepac-AYA model and derive data to permit modeling of long-acting art and prep regimens for AYA in south africa. Aim 2. Evaluate the clinical impact, cost, and cost-effectiveness of new AYA-focused treatment interventions to decrease opportunistic infections and mortality among AYA in south africa. Aim 3. Assess the clinical impact, cost, and cost-effectiveness of new AYA-focused prevention interventions to reduce HIV incidence among AYA in south africa. The goal of this proposal is to evaluate context-specific, adolescent-tailored care strategies and to identify the best use of limited resources to improve health outcomes for AYA affected by HIV in south africa. As new treatments and delivery systems emerge, the model will be poised to inform how to best deploy these resources for this vulnerable population.

Transactions

Action Obligated Date
Amendment $73,559
Amendment $720,954
Amendment $197,304
Amendment $0
Amendment $932,301
Amendment $7,945
Amendment $419,752
Amendment $786,575
Amendment $786,575
Amendment $792,840
Amendment $830,757
Original award $830,757
Show all 12

Subawards

Subrecipient Amount Awarded
Desmond Tutu Health Foundation Dr. Linda-Gail Bekker is Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town and… $270,863
Desmond Tutu Health Foundation Dr. Catherine Orrell is the head of Desmond Tutu Health Foundation (DTHF) Centre for Adherence and Therapeutics (DCAT) and a Professor in the Department of… $210,052
Desmond Tutu Health Foundation Dr. Linda-Gail Bekker is Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town and… $115,847
Yale Univ Dr. Paltiel will provide expertise and support for the ongoing development of the support the development of new model structure for the CEPAC-AYA mode… $226,360

Quick answers

Who received award R01HD111355?

R01HD111355 was awarded to The General Hospital Corporation by National Institute of Child Health and Human Development (National Institutes of Health) on September 20, 2022.

How much is award R01HD111355 worth?

$6,379,319 has been obligated on R01HD111355.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login